Plain-English translation of NCT07677839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying how lymph vessels (tiny channels that carry fluid through your body) normally look and work in breast cancer patients. They'll use a special type of ultrasound imaging combined with indocyanine green dye—a safe, FDA-approved dye that helps visualize these vessels—to create detailed maps of the lymph channels in your arm. This imaging happens before or during your planned lymph node surgery.
Doctors need better ways to understand and see lymph vessels in breast cancer patients to improve surgical planning and potentially reduce complications like arm swelling after surgery. This study will help create a clearer picture of what normal lymph vessel patterns look like.
You likely qualify if…
You likely don't qualify if…
Before or around the time of your scheduled lymph node surgery, you'll receive an injection of indocyanine green dye into your skin, followed by advanced ultrasound imaging of your forearm and upper arm to map the lymph vessels. The researchers will also track any reactions you have to the dye. The entire imaging session should take place during a single visit in coordination with your surgical care.
AI-generated summary from trial data · Sep 1, 2026 · Not medical advice
United States
Sponsor
University of California, Davis
Enrollment target
~50 participants
Started
June 2026
Primary completion
March 2036
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sheri Nichols
University of California, Davis
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.